Physician profile
William M Gerba
NPI 1568548949
$1,799.27
in general payments reported to CMS, 2019-2025
23 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $196 · 2021: $224 · 2022: $234 · 2023: $222 · 2024: $337 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $295.17 | 2020-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $265.15 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Glaxosmithkline, LLC. | $186.35 | 2019-2024 | Bexsero |
| Cranial Technologies, INC | $173.00 | 2020-2025 | Doc Band |
| Comsort, INC | $150.00 | 2019 | |
| Sanofi Pasteur INC. | $121.37 | 2019-2022 | |
| Alk-Abello, INC | $93.15 | 2024-2025 | Ragwitek, Grastek, Odactra |
| Cognoa, INC. | $68.36 | 2021-2022 | |
| Genzyme Corporation | $65.16 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.27 | 2023-2025 | Vpriv |
| Pfizer INC. | $51.20 | 2019-2024 | |
| Shire North American Group INC | $40.38 | 2019 | |
| Sobi, INC | $40.27 | 2019-2021 | |
| Aytu Biopharma, INC. | $28.41 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $21.43 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.80 | 2022 | |
| Genentech USA, INC. | $20.37 | 2020 | |
| Meridian Bioscience INC. | $19.11 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.81 | 2021 | |
| Tris Pharma INC | $18.16 | 2020 | |
| Neurelis, INC. | $17.96 | 2024 | Valtoco |
| Seqirus USA INC | $17.82 | 2023 | Flucelvax Quadrivalent |
| Lnhc, INC | $15.57 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gerba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.